Keywords: abbott, ra, drug, humira, potential, therapy, crohn
Abbott's RA drug Humira a potential therapy for Crohn's disease?
Article | 07 February 2005
Patients with active Crohn's disease who have ceased responding to Johnson & Johnson and Schering-Plough's Remicade (infliximab) may respond to Abbott ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
